18 results on '"Abdel Karim, Nagla Fawzy"'
Search Results
2. The pattern of KRAS mutations in non-small cell lung cancer (NSCLC): A retrospective study from south-eastern Georgia.
3. Blood based multigene testing using next generation sequencing to guide management in solid tumors: Experience from Augusta-Georgia.
4. Utilization and financial coverage of blood based next generation sequencing for solid tumors: A study from Augusta-Georgia.
5. Impact of tricyclic antidepressants, selective serotonin reuptake inhibitors, and other antidepressants on overall survival of patients with advanced lung cancer from 2004 to 2014: University of Cincinnati experience.
6. Retrospective study to assess the impact of hepatitis C virus infection on the prognosis and management of multiple myeloma.
7. Bosutinib in combination with pemetrexed in patients with selected metastatic solid tumors: A phase I study (NCT03023319).
8. Effect of personalized approach to therapy in non-small cell lung cancer (NSCLC) with liver metastasis with immunotherapy on outcomes.
9. Impact of tricyclic antidepressants, selective serotonin reuptake inhibitors, and other antidepressants on overall survival of patients with advanced lung cancer from 2004 to 2014: University of Cincinnati experience
10. Phase I trial of chloroquine (CQ)/hydroxychloroquine (HCQ) in combination with carboplatin-gemcitabine (CG) in patients with advanced solid tumors.
11. DNA damage response and repair (DDR) gene mutations and correlation with tumor mutation burden (TMB) in non-small cell lung cancer (NSCLC).
12. Correlation between K-RAS mutant subsets, TP53 mutation, and PD-L1 status in non-small cell lung cancer (NSCLC).
13. Tumor mutational burden (TMB) profile of K-RAS/TP-53 co-mutation in metastatic non-small cell lung cancer (m-NSCLC).
14. Impact of tricyclic antidepressants (TCAs), SSRIs, and other antidepressants on overall survival in patients with advanced lung cancer.
15. Impact of low molecular weight heparin on overall survival in patients with advanced lung cancer: A retrospective study.
16. Co-mutational status and PD-L1 expression in KRAS mutant non-small cell lung cancer (NSCLC): Role in treatment selection and association with clinical outcomes.
17. SWOG S1929: Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer (ES-SCLC).
18. Should we use small cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC)-based therapy for the treatment of large cell neuroendocrine cancer (LCNEC) of the lung?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.